What is the core patent for delgocitinib's industrial process?
The primary patent covering the industrial process for delgocitinib is U.S. Patent No. 9,750,793 [1]. This patent, filed by Nabla Pharmaceuticals, Inc., details a method for preparing a specific crystalline form of delgocitinib [1].
When does delgocitinib's manufacturing patent expire?
U.S. Patent No. 9,750,793 is set to expire on October 2, 2034 [1]. This expiration date is crucial for understanding when generic manufacturers might be able to produce delgocitinib.
How does delgocitinib's patent status compare to its therapeutic use?
While U.S. Patent No. 9,750,793 addresses the manufacturing process, other patents may cover the drug's therapeutic applications. For instance, U.S. Patent No. 10,003,567, also held by Nabla Pharmaceuticals, Inc., pertains to methods of treating conditions such as atopic dermatitis using delgocitinib [2]. This patent is expected to expire on October 2, 2034 [2]. Patent information for drugs is complex, and it is advisable to consult resources like DrugPatentWatch.com for a comprehensive view [3].
What are the potential challenges to delgocitinib's manufacturing patent?
Patents, including those for drug manufacturing processes, can be subject to legal challenges. Companies may seek to invalidate existing patents or find them to be unenforceable, which could lead to earlier market entry for generic versions. The specific patent landscape for delgocitinib should be monitored for any such legal proceedings [3].
Who is developing and marketing delgocitinib?
Currently, delgocitinib is being developed and marketed by Concert Pharmaceuticals, Inc. [4]. It is approved for the treatment of adults and adolescents 12 years of age and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies [4].